Genzyme reports mixed Renvela results |
|
|
|
Published
:
Mon, 18 Jun 2007 15:55
|
CAMBRIDGE, Mass. (AP) - Genzyme Corp. said Monday its kidney disease drug candidate Renvela showed mixed results in two studies, meeting its goal in one but failing in another.The drug candidate is a powdered formulation aimed at reducing serum phosphorus levels in kidney disease patients. The buildup of serum phosphorus can increase the risk of cardiovascular-related deaths in kidney disease patients. Genzyme applied for approval of the drug in tablet form in December. It plans on filing for approval of the powder form in the first half of 2008.The new study results compare Renvela to Genzyme's kidney disease treatment Renagel, which is in tablet form.In the first study, patients treated with the powder Renvela three times per day had phosphorus levels equivalent to patients taking Renagel three times per day, meeting the study's goal.In the second study, patients taking Renvela once per day had higher phosphorus levels than patients taking Renagel three times per day. The study failed to meet its goal of having Renvela prove at least as effective as Renagel.The results will be used to support approval for a three-times daily dosing of Renvela powder.Shares of Genzyme fell $1.42 to $65.48 in morning trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Genzyme to build plant in France 